What is Noetik?

Noetik is an AI-native biotechnology company using machine learning to increase clinical success rates for precision cancer therapies. By training AI models directly on human patient data, the company bridges the gap between drug development and human biology. Noetik's proprietary platforms, OCTO and Perturb-map, leverage the power of virtual cell models trained on massive multimodal data to identify therapeutic targets with unprecedented precision.

We are based in San Francisco, CA, and were founded in 2022 by biotech and AI veterans from Recursion Pharmaceuticals, Genentech, and the Parker Institute for Cancer Immunotherapy.

Our investors include Polaris Partners, DCVC, Breakout Ventures, Khosla Ventures, Wittington Ventures, Zetta Venture Partners, 11.2 Capital, Epic Ventures, Catalio Capital Management, Intermountain Ventures, North South Ventures, Nomads, CJNV Bioventures, ApSTAT Technologies, Linearis Labs and Ventures Fund.

To learn more about Noetik, visit https://www.noetik.ai, and if you’re interested in partnering with us, please reach out to info@noetik.ai!